| 1 |
Blakey JD, Wardlaw AJ. What is severe asthma? Clin Exp Allergy 2012;42:617-624.
DOI
ScienceOn
|
| 2 |
Kim SH, Kim TW, Kwon JW, et al. Economic costs for adult asthmatics according to severity and control status in Korean Tertiary Hospitals. J Asthma 2012;49:303-309.
DOI
ScienceOn
|
| 3 |
Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-413.
DOI
ScienceOn
|
| 4 |
Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32-39.
DOI
ScienceOn
|
| 5 |
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma: European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477.
DOI
ScienceOn
|
| 6 |
Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66:910-917.
DOI
ScienceOn
|
| 7 |
Kim TB, Park CS, Bae YJ, Cho YS, Moon HB; COREA Study Group. Factors associated with severity and exacerbation of asthma: a baseline analysis of the cohort for reality and evolution of adult asthma in Korea (COREA). Ann Allergy Asthma Immunol 2009;103:311-317.
DOI
ScienceOn
|
| 8 |
Haselkorn T, Lee JH, Mink DR, Weiss ST; TENOR Study Group. Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2008;101:256-263.
DOI
ScienceOn
|
| 9 |
Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-813.
DOI
ScienceOn
|
| 10 |
Bel E, ten Brinke A. A rational approach to the management of severe refractory asthma. Treat Respir Med 2005;4: 365-379.
DOI
ScienceOn
|
| 11 |
Wenzel SE, Busse WW; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:14-21.
DOI
ScienceOn
|
| 12 |
Lee JH, Haselkorn T, BorishL, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR Study. Chest 2007;132:1882-1889.
DOI
ScienceOn
|
| 13 |
Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-1036.
|
| 14 |
Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
DOI
ScienceOn
|
| 15 |
Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-993.
DOI
ScienceOn
|
| 16 |
Kim SH, Yoon HJ. Use of the exhaled nitric oxide for management of asthma and respiratory diseases. Korean J Med 2008;74:579-586.
|
| 17 |
Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-395.
DOI
ScienceOn
|
| 18 |
Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-1098.
DOI
ScienceOn
|
| 19 |
Al-Ramli W, Préfontaine D, Chouiali F, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009;123:1185-1187.
DOI
ScienceOn
|
| 20 |
Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-323.
DOI
ScienceOn
|
| 21 |
Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012;185:356-362.
DOI
ScienceOn
|
| 22 |
Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 201242:650-658.
DOI
ScienceOn
|
| 23 |
Moore WC, Evans MD, Bleecker ER, et al. Safety of investigative bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol 2011;128:328-336.
DOI
ScienceOn
|
| 24 |
Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma: data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011;183:299-309.
DOI
ScienceOn
|
| 25 |
Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010;125:1028-1036.
DOI
ScienceOn
|
| 26 |
Cohen L, E X, Tarsi J, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007;176:138-145.
DOI
ScienceOn
|
| 27 |
Busacker A, Newell JD Jr, Keefe T, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009;135:48-56.
DOI
ScienceOn
|
| 28 |
Bergeron C, Fukakusa M, Olivenstein R, et al. Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma. J Allergy Clin Immunol 2006;117:703-705.
DOI
ScienceOn
|
| 29 |
Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109:649-657.
DOI
ScienceOn
|
| 30 |
Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006;174:134-141.
DOI
ScienceOn
|
webmaster
